Key clinical point: Serious adverse events can occur in patients treated only with placebo in cancer clinical trials.
Major finding: The incidence of grade 3-4 placebo adverse events was 18% in cancer clinical trials.
Study details: Systematic review and meta-analysis of 10 randomized, placebo-controlled, double-blind trials.
Disclosures: No conflicts of interest were declared.
Chacón M et al. JAMA Network Open. 2018 Dec 7. doi: 10.1001/jamanetworkopen.2018.5617.
This Week's Must Reads
Must Reads in Renal Cell Carcinoma
First-line avelumab/axitinib for RCC benefits wide range of patients, Choueiri TK et al. GUCS 2019, Abstract 544.
Strong link found between RCC and melanoma, Kim KB et al. Cancer Epidemiol. 2018 Oct 19;57:80-4
Apo B/A1 predicts survival in metastatic renal cell carcinoma, Zhang F et al. Urol Oncol. 2018 Nov 30. doi: 10.1016/j.urolonc.2018.11.010